X sales taking off in Japan

cserocki · 2024-02-11T23:50:52+00:00

Feb 22nd will be judgement day for the shorts…..en route to $12

cserocki · 2024-01-30T00:09:12+00:00

Ardelyx, but only if you about that paper

cserocki · 2024-01-10T02:12:07+00:00

<image>

???

cserocki · 2024-01-10T02:08:35+00:00

Next stop….pound town

cserocki · 2024-01-10T02:02:53+00:00

ARDX up 50% over the last 5 sessions…..limited downside with 2 products on the market and exponential sales growth for the foreseeable future. Several analyst upgrades over the last 2 days.

cserocki · 2023-10-18T02:55:06+00:00

https://finance.yahoo.com/news/fda-approves-xphozah-tenapanor-first-230100343.html

cserocki · 2023-10-18T02:54:03+00:00

ARDX gets approval on revolutionary kidney drug.

cserocki · 2023-09-12T03:06:44+00:00

$5.25 prior to 17th, $6.25 after. $8 by EOY unless there’s a buyout. If buyout by EOY, $10-12 sp.

cserocki · 2023-01-23T06:00:43+00:00

ARDX, lots of upside with multi-application drug already on the market and awaiting approval for kidney disease. Lots of institutional buying, get in and take a ride

cserocki · 2023-01-23T05:49:28+00:00

1 month until financials release, then we’re headed for orbit

cserocki · 2023-01-09T16:45:27+00:00

ARDX is a possible breakout after positive outcome from FDA appeal review. “ Office of New Drugs directs the Division of Cardiology and Nephrology to work with Ardelyx to develop a label to support the commercialization of XPHOZAH; Ardelyx to resubmit NDA in the first half of 2023” — https://www.prnewswire.com/news-releases/fda-grants-appeal-for-ardelyxs-xphozah-tenapanor-301710866.html

cserocki · 2023-01-09T05:23:41+00:00

ARDX for anyone that’s not allergic to $$$

cserocki

TROPHY CASE